▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2606 by analyst upside · 2026-06-29
NBIX
Neurocrine Biosciences, Inc.
Healthcare · Market Cap $17B · P/E 25.9x
ANALYST PRICE TARGET
+15.3%
implied upside to consensus target
Current Price $168.52
Consensus Target $194.38
Bull Target $250.65
Bear Target $144.0
Analysts Covering 28
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
20
Hold
4
Sell
0
52-Week Low $122.14
52-Week High $169.57
YTD Return +19.9%
FUNDAMENTALS
Market Cap $17B
P/E Ratio (TTM) 25.9x
Forward P/E 13.3x
EPS (TTM) $6.50
PEG Ratio 0.48
Dividend Yield N/A
Revenue (TTM) $3.1B
Profit Margin 21.6%
52-WEEK RANGE
52-Week Low $122.14
52-Week High $169.57
Current Price $168.52
Bear Target $144.0
Bull Target $250.65
● Now $168.52 ● Target $194.38
TRADING DATA
Avg Volume 1.2M
YTD Return +19.9%
Analyst Count 28
Consensus Buy
Upside to Target +15.3%
Last Updated 2026-06-29

ANALYST SUMMARY

Neurocrine Biosciences, Inc. (NBIX) is currently trading at $168.52 with a Wall Street consensus price target of $194.38, implying potential upside of 15.3% over the next 12 months. 28 analysts currently cover NBIX, with a consensus rating of Buy - 86% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $250.65, while the most cautious has a target of $144.0.

NBIX operates in the Healthcare sector with a market capitalisation of $17B. The stock is up 19.9% year-to-date and is currently trading near the upper end of its 52-week range of $122.14 – $169.57.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ZBH +6.0%
Zimmer Biomet Holdings, Inc.
$18B · P/E 24.1x · Hold
STE +19.1%
STERIS plc
$21B · P/E 27.2x · Buy
THC +28.7%
Tenet Healthcare Corporation
$16B · P/E 9.8x · Buy
LH +14.2%
Labcorp Holdings Inc.
$22B · P/E 24.0x · Buy
SOLV +3.3%
Solventum Corporation
$14B · P/E 9.7x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for NBIX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital — Reiterated
Outperform → Outperform 2026-05-29 Building track record
Bernstein ● Initiated
Outperform 2026-05-22 Building track record
JP Morgan — Reiterated
Overweight → Overweight 2026-05-08 43% win rate (7 calls)
Truist Securities — Reiterated
Buy → Buy 2026-05-07 Building track record
Citigroup — Reiterated
Buy → Buy 2026-05-06 Building track record
Morgan Stanley — Reiterated
Equal-Weight → Equal-Weight 2026-05-06 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2026-05-06 Building track record
Piper Sandler — Reiterated
Overweight → Overweight 2026-05-06 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
65
out of 100
Coverage depth
26/30
Consensus clarity
17/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →